In a study reported in a research letter in JAMA Oncology, Nimgaonkar et al found that less than half of patients with urothelial cancer who had received first-line platinum-based therapy underwent testing for FGFR alterations and that less than half of patients with susceptible alterations received targeted therapy with the FGFR inhibitor erdafitinib. Among patients who received erdafitinib, overall survival was similar to that observed in clinical trials.
The study used the Flatiron Health database to identify patients with advanced urothelial cancer who received first-line platinum-based chemotherapy and started a later line of therapy between May 2016 and September 2021. The likelihood of initiating erdafitinib compared with standard second-line immunotherapy (atezolizumab, the first approved immune checkpoint inhibitor) in the 6-month interval after each drug’s approval was assessed.
Read More: https://ascopost.com/news/june-2022/real-world-uptake-of-fgfr-alteration-testing-and-gene-targeted-therapy-for-patients-with-urothelial-cancer/